This article discusses the use of dupilumab, a monoclonal antibody, as a treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP). The study aimed to identify predictive biomarkers for the response to dupilumab in CRSwNP patients. The researchers analyzed the populations of innate lymphoid cells (ILCs) in the blood of patients before treatment and categorized them into fast, normal, and slow responders based on clinical outcomes. They found that increased frequencies of conventional ILC2s were associated with fast responders, while increased frequencies of ILC3s were associated with slow responders. Additionally, they observed increased numbers of inflammatory ILC2s in fast responders. The study suggests that baseline frequencies of inflammatory ILC2s may be a predictor for patients' responses to dupilumab. However, the small sample size and selection bias of the study should be considered when interpreting the results. [Extracted from the article]